NDATOPICALSOLUTION
Approved
Mar 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
4/8 — Partial
DOVONEX (calcipotriene) by PleoPharma is clinical pharmacology in humans, the natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin d 3 (cholecalciferol) in the skin. Approved for psoriasis. First approved in 1997.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOVONEX (calcipotriene) is a synthetic vitamin D3 analog administered as a topical solution for the treatment of psoriasis. It works by modulating vitamin D-dependent pathways; approximately 6% of the applied dose is systemically absorbed and rapidly metabolized via hepatic pathways similar to natural vitamin D metabolism.
LOE Approaching
Product approaching end-of-life with modest competitive pressure (30% intensity); team size likely contracted or consolidated into broader dermatology portfolios.
Mechanism of Action
CLINICAL PHARMACOLOGY In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D 3 (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D 3 . Clinical studies with…
Indications (1)
Worked on DOVONEX at PleoPharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.